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Abstract. Parkinson’s disease (PD) is the second most common neurodegenerative disease worldwide. Considering the
devastating symptoms, high prevalence, and lack of definitive diagnostic test, there is an urgent need to identify possible
biomarkers and new therapeutic targets. Genes identified and/or proposed to be linked to PD encode proteins that fulfill diverse
roles in cellular functions. There is a growing interest in identifying common traits which lead to the disease. Long non-coding
RNAs have recently emerged as possible regulatory hubs of complex molecular changes affecting PD development. Among
them, NEAT1 has attracted particular interest. It is a major component and the initiator of nuclear paraspeckles, thus regulating
transcription and modifying protein functions. This review summarizes data available on the role of NEAT1 in PD. NEAT1
upregulation in PD has repeatedly been reported, however, whether this is part of a protective or a damaging mechanism is
still a topic of debate. It has been proposed that NEAT1 propagates PD via its interaction with PINK1 and several micro
RNAs and by modulating SNCA expression. On the other hand, findings of NEAT1 acting as a bona fide LRRK2 inhibitor
argue for its protective role. These contradictory results could be due to the different disease models implemented. This calls
attention to the difficulties posed by the complex patho-mechanisms of neurodegenerative disorders and the limitations of
disease models. However, the potential of NEAT1 as a biomarker and as a therapeutic target for PD highly warrants further
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24
INTRODUCTION25
Parkinson’s disease (PD) is the second most com-26
mon neurodegenerative disease, affecti g approxi-27
mately 1-2% of the population over the age of 65 [1].28
The prevalence of the disease increases exponentially29
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with age, causing millions of deaths each year [2]. 30
The characteristic motor symptoms of PD are often 31
accompanied by various non-motor symptoms, exac- 32
erbating disease severity. In the absence of an early 33
diagnostic test, PD diagnosis is based on the cardinal 34
motor symptoms. However, by the time these man- 35
ifest, the majority of the dopaminergic neurons in 36
the substantia nigra have been irreversibly lost [3–5]. 37
Despite the intensive research focusing on develop- 38
ment of disease-modifying therapies [6], so far no 39
effective treatment is available. Given the devastating 40
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symptoms, high prevalence, and lack of a specific41
diagnostic test, there is an urgent need to identify pos-42
sible biomarkers and new therapeutic targets for PD.43
PD is a complex multifactorial disease, the exact44
patho-mechanism of which has yet to be fully elu-45
cidated. Besides various environmental and lifestyle46
factors identified as triggers and/or facilitators of47
the disease [7], several genetic alterations have been48
found to be related to the disorder. In addition to49
21 PARK genes described in the human genome as50
potential direct culprits of the disease [8], genetic51
variants of 26 loci have been proposed to be disease52
risk modifiers [9, 10]. These genes encode proteins53
that fulfill roles in diverse cellular functions, such54
as synaptic transmission, vesicle transport, protein55
transport and degradation, autophagy, mitochondrion56
maintenance and energy homeostasis [11]. There is a57
growing interest in identifying common traits behind58
the diverse mechanisms causing malfunctions which59
lead to PD.60
Due to their versatile roles in cellular functions,61
long non-coding RNAs (lncRNAs) have recently62
emerged as possible regulatory hubs of complex63
molecular changes affecting PD development. lncR-64
NAs are RNA polymerase II transcripts over 20065
nucleotides in length, without long open reading66
frames. They are frequently polyadenylated, alterna-67
tively spliced and capped, thus having an mRNA-like68
structure [12]. lncRNAs have gained attention in69
relation to neurodegenerative diseases due to the70
diverse mechanisms by which they can affect cel-71
lular homeostasis [13]. lncRNAs are known to exert72
regulatory roles on gene expression by modulating73
histone post-translational modifications and tran-74
scription factor activities, participating directly in75
post-transcriptional mRNA modifications, acting as76
ceRNAs (competing endogenous RNAs) that can77
sponge micro RNAs (miRNAs) and possibly by sev-78
eral other mechanisms acting at translational and79
post-translation levels (for a review, see [12, 14]).80
NEAT1 lncRNA has attracted particular interest81
in the past few years since its levels have been82
shown to be altered in neurodegenerative diseases83
(reviewed in [15]). The possibility of a direct relation84
between NEAT1 and PD has been strengthened by85
recent findings on NEAT1 effects on mitochondrial86
function [16], detection of elevated NEAT1 levels in87
postmortem PD brain samples [17, 18] and recently88
our research group detected elevated NEAT1 lev-89
els also in the peripheral blood of PD patients [19].90
However, the questions whether a change in NEAT191
level is in causal relationship with alleviation or92
aggravation of PD, or alternatively, NEAT1 lncRNA 93
is a bystander in PD pathogenesis, without being 94
actively involved in the disease course, are still 95
unanswered. In this review we summarize recently 96
published data related to the possible role of NEAT1 97
in PD. Similarly to the seemingly contradictory views 98
which attribute both oncogenic and tumor-suppressor 99
roles to NEAT1 lncRNA in cancer [20, 21], recently 100
published data suggest both protective and enhancing 101
roles for NEAT1 in neurodegeneration. We critically 102
review these reports with particular attention to PD 103
in order to facilitate a clearer view on the possible 104
involvement of this lncRNA in the disease. We hope 105
that calling attention to the topic will help clarify con- 106
trasting data and raise questions for further research. 107
NEAT1: DISCOVERY, GENE STRUCTURE, 108
EXPRESSION 109
NEAT1 (Nuclear Enriched Abundant Transcript 1, 110
later changed to Nuclear Paraspeckle Assembly Tran- 111
script) lncRNA was first described in 2007 as a highly 112
abundant nuclear RNA [22]. In human, NEAT1 is 113
transcribed from the multiple endocrine neoplasia 114
(MEN) type I locus on the long arm of chromo- 115
some 11 [23]. Transcription results in two NEAT1 116
isoforms: the shorter NEAT1 1 (alias MENepsilon) 117
is 3 684 nucleotides, while the longer NEAT1 2 (alias 118
MENbeta) is 22 743 nucleotides. For simplicity we 119
will refer to the former as NEAT1S and to the lat- 120
ter as NEAT1L. NEAT1 related genes are specific 121
to mammals [24] and the gene sequence is well 122
conserved across mammalian species [25], which is 123
an uncommon feature of lncRNAs is general [22]. 124
Mouse NEAT1 isoforms are smaller than the human 125
ones (3.7 and 20 kb), but are in similar relation to each 126
other as the human ones (see more on this below). 127
The two NEAT1 isoforms are transcribed by RNA 128
polymerase II from the same promoter under the 129
same transcriptional control. NEAT1S is produced by 130
early 3’end processing of the transcript at a canonical 131
polyadenylation site. NEAT1L results from suppres- 132
sion of polyadenylation at this site. Its 3’ end is 133
formed without poly(A) tail by RNase P cleavage at a 134
tRNA-like structure [26, 27]. Consequently, the two 135
isoforms overlap over the full length of NEAT1S that 136
corresponds to the 5’ end sequence of NEAT1L. The 137
proportion of the two NEAT1 isoforms produced is 138
determined through the regulation of poly(A) addi- 139
tion; however, it remains to be elucidated how this 140
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The shorter NEAT1 isoform is generally observed142
in higher quantities and in a wider range of tissues.143
Nonetheless, the function of NEAT1S is less clear144
compared to that of NEAT1L which is indisputably145
the major structural component of paraspeckles.146
Paraspeckles are subnuclear ribonucleoprotein com-147
plexes within the interchromatin space in mammalian148
cells [28, 29]. These complexes are assembled from149
RNAs and various proteins many of which have RNA150
binding affinity. Paraspeckles play roles in regulating151
transcription and RNA processing by several mech-152
anisms which include retaining RNA and proteins,153
modulating RNA editing and splicing and acting as154
sponges for miRNAs (reviewed in [30]). Knockdown155
of NEAT1L production results in paraspeckle elimi-156
nation even in the presence of intact NEAT1S [31].157
NEAT1L folds end-to-end within paraspeckles with158
5’ and 3’ ends of the lncRNA localizing on the periph-159
ery while the core is positioned in the center of the160
structure. As the 5’ ends of the two NEAT1 isoforms161
are identical, this may suggest that the short isoform162
is also localized in the periphery of paraspeckles [32].163
However, recent findings argue against NEAT1S as a164
major paraspeckle component, instead revealing the165
short isoform to be localized in foci termed ‘micro-166
speckles’ [32–34]. Mice lacking the long isoform of167
NEAT1 show defects in female reproductive tissue168
development while absence of the short isoform does169
not cause any obvious external or histological abnor-170
malities [35, 36]. These findings raised the possibility171
of NEAT1S being a by-product without any specific172
role [36]. However, the observations that NEAT1L173
and NEAT1S accumulate differently in and have dif-174
ferent effects on some cancer types [21, 37–39] and175
that overproduction of NEAT1S increases resistance176
of cells to oxidative stress [40] refute this notion.177
The observation that NEAT1S is more conserved in178
evolution and is generally more abundant, together179
with it being detected outside of paraspeckles [33]180
may also serve as an indirect argument for an as yet181
unidentified paraspeckle-independent function of this182
isoform.183
While there is a general consensus on the pro-184
duction of the two NEAT1 variants, the existence of185
further isoform(s) is less clear. The Human Genome186
Ensemble (GRCH38.p13) depicts nine NEAT1 splice187
variants. Some of these are “annotated manually”188
while others are products of the “manually super-189
vised computational pipeline”. These transcripts bear190
small differences in their 5’regions, due to five short191
putative introns. As there are no reported RNA map-192
ping results to verify the removal of these, it remains193
open if any of the depicted NEAT1 splice variants 194
deserve particular attention. Among the few reports 195
on NEAT1 isoforms Chowdhury et al. mention, 3 196
out of 8 NEAT1 variants to be upregulated in human 197
endothelial cells after LPS (lipopolysaccharide) treat- 198
ment [41] and Kessler et al. found differences in the 199
expression levels of 3 variants (NEAT1-201, NEAT1- 200
202/v2, and NEAT1-205) by comparing NEAT1 201
RNAs in hepato-cellular carcinoma and normal tissue 202
samples [39]. 203
Data on NEAT1 lncRNA expression, tissue dis- 204
tribution and function have been obtained primarily 205
from mouse models which permit genome editing 206
of the gene and from cancer related studies using 207
tumor samples and various human cell lines. Due 208
to space constraints these will not be reviewed here; 209
instead we call attention only to data which exemplify 210
the diverse, frequently contrasting effects attributed 211
to NEAT1 lncRNAs. In the following sections we 212
review very recent data related to possible NEAT1 213
functions in neurodegenerative disorders and mod- 214
els of these focusing primarily on PD. Excellent 215
recent reviews on the regulation of NEAT1 lncRNA 216
expression and the contribution of NEAT1 to tumor 217
development can be found in [21, 42, 43]. 218
CELLULAR FUNCTIONS AFFECTED BY 219
NEAT1 220
Shortly after the description of NEAT1, it was 221
demonstrated that the lncRNA localizes to specific 222
nuclear ribonucleoprotein structures. Subsequent 223
studies proved that NEAT1L knockdown leads 224
to paraspeckle disintegration while overexpression 225
increases paraspeckle abundance; furthermore details 226
on the folding of the RNA within paraspeckles as 227
well as on the protein components of the complex 228
were revealed [32, 44]. However, the involvement of 229
NEAT1S in paraspeckles remains disputed. NEAT1’s 230
role in paraspeckle scaffolding imply an effect on 231
cellular functions: paraspeckles regulate transcrip- 232
tion and RNA maturation via accumulation of protein 233
factors. The amount of paraspeckles affects the reten- 234
tion of A-I edited RNAs, mitoRNAs (mitochondrial 235
protein coding RNAs) and miRNAs. Changes in the 236
level of NEAT1 modulate functions via these. A 237
further mechanism of NEAT1 action which may or 238
may not be associated with paraspeckles is acting 239
as ceRNA by sponging miRNAs. This seems to be a 240
major means by which NEAT1 affects carcinogenesis 241
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Fig. 1. Proposed mechanisms by which NEAT1 affects the course of PD. For a detailed description please see the corresponding sections
of the text. NEAT1, Nuclear Paraspeckle Assembly Transcript 1; PINK1, protein phosphatase and tensin homolog (PTEN)-induced kinase
1; SNCA, Alpha-synuclein (gene); GJB1, Gap junction beta-1 (gene); -syn, Alpha-synuclein (protein); NLRP3, NOD-, LRR- and pyrin
domain-containing protein; RAB3IP, RAB3A interacting protein (gene); LRRK2, Leucine-rich repeat kinase 2.
Paraspeckles are dispensable under normal labo-243
ratory conditions but play essential roles when cells244
are placed under stress. In accord with this several245
cellular stressors enhance NEAT1 expression and246
paraspeckle formation. This is well reflected by the247
multitude of transcription factors known to affect248
NEAT1 expression. A comprehensive review on this249
topic was recently published by [43].250
NEAT1 IN PARKINSON’S DISEASE251
Altered expression of NEAT1 has been reported252
in various neurodegenerative diseases (reviewed in253
[15]), among them in PD. Elevated NEAT1 levels254
were reported in human postmortem brain samples255
of various brain areas, such as in the substantia nigra256
and anterior cingulate gyrus [17, 18]. Upregulation of257
the lncRNA was found to increase with progression of258
the disease [17]. Besides the central nervous system259
(CNS), elevated NEAT1 levels were also reported in 260
the peripheral blood of PD patients [19]. 261
In this review we summarize data available on the 262
role of NEAT1 in PD pathogenesis obtained from 263
in vitro and in vivo models of the disease (Fig. 1). 264
As demonstrated by results shown below, various 265
stressors lead to the upregulation of NEAT1 RNA; 266
however, the role that NEAT1 plays in PD is still 267
a topic of debate. Some of the data indicate that 268
NEAT1 upregulation has a detrimental effect and 269
accelerates disease progression. Other observations 270
suggest a compensatory mechanism by which the 271
RNA might promote cell survival and arrest disease 272
pathology (Figs. 1–4). Finally, it may be that NEAT1 273
has no significant effect on PD pathogenesis and the 274
observed changes in RNA merely reflect a bystander 275
effect on NEAT1 in the disease process. In the follow- 276
ing sections we summarize available data supporting 277
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upregulation in the course of PD. Table 1 and Fig. 1279
show brief summaries of reported results obtained by280
alterations of NEAT1 lncRNA levels using different281
PD models and the mechanisms assumed, respec-282
tively. Figs. 2–4 show observed effects of NEAT1283
highlighting reported data in respects of PD models284
(animal and cellular models: Fig. 2 vs. Fig. 3) and285
toxins used (Fig. 3 vs. Fig. 4).286
Fig. 2. Observed effects of NEAT1 in animal models of PD.
For a detailed description please see the corresponding sections
of the text. MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine;
NEAT1, Nuclear Paraspeckle Assembly Transcript 1; TH, Tyrosine
hydroxylase.
NEUROTOXIC NEAT1 EFFECTS 287
To date, seemingly more data support the notion of 288
NEAT1 downregulation being protective against PD 289
progression. 290
In a study Yan and colleagues found that treatment 291
of mice with MPTP (1-methyl-4-phenyl-1,2,3,6- 292
tetrahydropyridine) led to a rise in the expression 293
of NEAT1, alongside an increase in the protein 294
levels of PINK1 (phosphatase and tensin homolog 295
(PTEN)-induced kinase 1) and LC3-II/LC3-I ratio 296
(LC3: Microtubule-associated protein light chain 3) 297
in the midbrain of the animals [45]. The detrimental 298
effect of MPTP on neuronal cell survival was demon- 299
strated by the significant decrease in the number of 300
TH+cells (Fig. 2). The tyrosine hydroxylase enzyme 301
catalyzes the transformation of the amino acid L- 302
tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA) 303
and is a marker of dopaminergic neurons in the CNS. 304
NEAT1 silencing significantly increased the number 305
Fig. 3. Observed effects of NEAT1 in the MPP+cell model of PD. For a detailed description please see the corresponding sections of the
text. MPP+, 1-methyl-4-phenylpyridinium; NEAT1, Nuclear Paraspeckle Assembly Transcript 1; PINK1, protein phosphatase and tensin
homolog (PTEN)-induced kinase 1; SNCA, Alpha-synuclein (gene); NLRP3, NOD-, LRR- and pyrin domain-containing protein; GJB1, Gap
junction beta-1; RAB3IP, RAB3A interacting protein (gene); ROS, Reactive oxygen species; SOD, Superoxide dismutase; LDH, Lactate
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Fig. 4. Observed effects of NEAT1 in the PQ and tBHP cell models of PD. For a detailed description please see the corresponding sections
of the text. PQ, Paraquat; tBHP, tert-Butyl hydroperoxide; NEAT1, Nuclear Paraspeckle Assembly Transcript 1; ROS, Reactive oxygen
species.
of TH+neurons and led to a significant decrease in306
PINK1 protein levels. These changes were accom-307
panied by the elevation of LC3I and decrease of308
LC3-II protein levels. LC3-II is an autophagosome309
marker, converted from the cytoplasmic LC3-I. The310
membrane bound LC3-II protein plays a role in the311
formation and elongation of the autophagosome [46].312
The reduced LC3-II/LC3-I ratio is an indicator of313
decreased autophagy. In vitro studies involving the314
SH-SY5Y cell model of the disease yielded similar315
results: elevated expression of NEAT1 and PINK1316
protein and increased LC3-II/LC3-I ratio were317
detected upon MPP+(1-methyl-4-phenylpyridinium;318
the active metabolite of MPTP) exposure. Con-319
versely, knockdown of the lncRNA decreased the320
MPP+induced high expression of PINK1 protein,321
reversed the change in LC3-II/LC3-I ratio and322
improved cell viability (Fig. 3). Intriguingly, overex-323
pression of PINK1 reversed the beneficial effects of324
NEAT1 silencing on cell survival. This observation325
raised the possibility that NEAT1 exerts its effects326
in a PINK1-dependent manner. Yan and colleagues327
proposed that the lncRNA might bind directly to the328
protein and stabilize it by influencing its ubiquitina- 329
tion and preventing its degradation. Elevated NEAT1 330
level thus leads to an increase in PINK1 level [45] 331
(Fig. 1). 332
Based on these in vivo and in vitro observations, 333
Yan et al. concluded that NEAT1 upregulation is 334
detrimental since by stabilizing PINK1 protein the 335
lncRNA promotes autophagy [45]. In accord with 336
this, knocking down the lncRNA proved to be pro- 337
tective against MPP+/MPTP induced cell loss. 338
The finding on the protective effect of NEAT1 339
silencing was strengthened by Liu and Lu [47]. In 340
their experiments MPTP treatment of mice led to 341
a reduction in the number of TH+cells in the brain 342
and NEAT1 upregulation was observed in both in 343
vivo and in vitro models of the disease (Figs. 2 344
and 3). In MPP+treated SH-SY5Y cells knockdown 345
of NEAT1 improved cell viability and diminished 346
cell apoptosis as indicated by decreased Bax/Bcl-2 347
ratio and caspase activity. Upon NEAT1 silencing a 348
downregulation in SNCA (Alpha-synuclein) expres- 349
sion was observed. Intriguingly, the beneficial effects 350
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apoptosis could be reversed by overexpressing the352
SNCA gene. These findings suggest that upregulation353
of NEAT1 is harmful in the course of PD via an -syn354
related mechanism (Fig. 1).355
According to a more recent study by Sun et 356
al. [48], MPP+treatment not only caused upregu- 357
lation of NEAT1 but also enhanced expression of 358
-syn, GJB1 (Connexin32, Cx32; gap junction beta 359
Table 1




Toxin Effect of toxin NEAT1
interven-
tion
Effect of NEAT1 intervention Proposed NEAT1 mode
of action
Reference
mouse MPTP increase in: NEAT1
silencing
decrease in: Stabilizes, thus increases
the level of PINK1
protein
[45]
- NEAT1 expression - PINK1 protein level
- PINK1 protein level - LC3-II/LC3-I ratio
- LC3-II/LC3-I ratio
decrease in the number of
TH+neurons




MPP+ increase in: NEAT1
silencing
decrease in:
- NEAT1 expression - PINK1 protein level
- PINK1 protein level - LC3-II/LC3-I ratio
- LC3-II/LC3-I ratio
increase in cell viability
mouse MPTP increase in NEAT1
expression decrease in the
number of TH+neurons
n.a. n.a. Upregulation of SNCA [47]
SH-SY5Y
cells













MPP+ enhanced expression of: NEAT1
silencing
decreased expression of:
- SNCA - SNCA Sponges miR-1301-3p







- GJB - NLRP3
- NLR3P - caspase-1
- IL-1 - IL-1
- caspase-1
- Bax increased miR-1301-3p
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NEAT1, Nuclear Paraspeckle Assembly Transcript 1; PINK, phosphatase and tensin homolog (PTEN)-induced kinase 1; TH, Tyrosine
hydroxylase; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MPP+, 1-methyl-4-phenylpyridinium; GJB, gap junction beta 1; NLR3P,
nucleotide oligomerization domain-like receptor protein with pyrin domain containing 3; IL-1, interleukin-1; IL-6, interleukin-6; TNF-
, Tumor necrosis factor ; RAB3IP, RAB3A-interacting protein; SOD, Superoxide dismutase; LDH, Lactate dehydrogenase; SNCA,
Alpha-synuclein gene; ROS, Reactive oxygen species.
1), NLRP3 (nucleotide oligomerization domain-like360
receptor protein with pyrin domain containing 3), IL-361
1 and apoptosis factors caspase-1 and Bax, while362
Bcl-2 and the miRNAs miR-1301-3p and miR-5047363
were downregulated (Fig. 3).364
NLRP3 containing inflammasome is a protein365
complex of NLRP3, ASC (Apoptosis-associated366
speck-like protein containing a CARD) and caspase-367
1, which has been identified to play a pathologic368
role in neuroinflammation related to various neurode-369
generative diseases. Upon activation, inflammasomes370
provoke innate immune responses by secreting pro-371
inflammatory cytokines such as IL-1 and IL-18372
and by promoting pyroptosis, a caspase 1-dependent373
cell death which contributes to the propagation of374
inflammation via the release of further inflammatory375
markers [49]. In murine models of PD NLRP3 inflam-376
masome was found to be activated by fibrillar -syn377
and by the degeneration of dopaminergic neurons378
themselves [50]. The cardinal role of inflammasome379
activation in PD pathology is supported by findings380
obtained both from studies involving animal models381
and human samples. Treatment with small molecule382
NLRP3 inhibitors inhibited inflammasome activation383
and effectively mitigated motor deficits, nigrostriatal384
dopaminergic degeneration, and accumulation of -385
syn aggregates in various rodent models of the disease386
[50]. Further studies showed that absence of either387
NLRP3 or caspase 1 was protective against the devel-388
opment of PD symptoms and loss of neurons in the389
substantia nigra after treatment with rotenone and 390
MPTP, respectively (reviewed in [51]). 391
GJB1 (alias connexin-32 (Cx32)) is a member of 392
the gap junction connexin family. The protein has 393
recently been reported to play a central role in the 394
uptake of -syn oligomeric assemblies in neurons and 395
oligodendrocytes [52]. In vitro and in vivo models of 396
PD demonstrated a correlation between the upregula- 397
tion of GJB1 and accumulation of -syn aggregates. 398
The correlation is established by a positive feedback 399
loop: in vitro studies demonstrated that GJB1 over- 400
expressing cells are more prone to -syn oligomer 401
uptake, and both exposure to -syn aggregates and 402
overexpression of the SNCA gene leads to upregula- 403
tion of GJB1 [52]. These findings underpin the role of 404
GJB1 in the pathophysiology of PD and raise the pos- 405
sibility of GJB1 expression modulation as a feasible 406
way of therapeutic intervention [52]. 407
In the study of Sun and colleagues, NEAT1 knock- 408
down in MPP+treated SH-SY5Y cells reversed the 409
neurotoxic effects, as indicated by a significant 410
decrease in the number of apoptotic cells and by 411
the suppression of -syn, NLRP3, caspase-1 and 412
IL-1 expression (Fig. 3). Overexpression of -syn 413
reversed the anti-apoptotic effects of NEAT1 silenc- 414
ing. These findings are in line with the results of 415
Liu and Lu as discussed earlier [47], namely that 416
NEAT1 downregulation improves cell survival via 417
decreasing -syn expression by an as yet unidenti- 418
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-syn modulating ability of NEAT1 is linked to the420
miR-1301-3p/GJB1 pathway [48] (Fig. 1). This was421
based on their findings that NEAT1 downregulation422
led to increased miR-1301-3p expression, while inhi-423
bition of the micro RNA diminished the protective424
effects of NEAT1 silencing. The latter effects were425
demonstrated by the increased number of apoptotic426
cells and by the promotion of both transcription and427
translation of GJB1. Reporter gene assays revealed428
direct interactions between both NEAT1/ miR-1301-429
3p and miR-1301-3p/GJB1, leading to the conclusion430
that the lncRNA serves as an endogenous sponge for431
miR-1301-3p [48]. NEAT1 silencing prevents spong-432
ing of the miRNA thus miR-1301-3p can thus exert433
its inhibitory effect on GJB1 expression and through434
this prevent -syn induced activation of the NLRP3435
inflammasome.436
Besides these observations, it has been proposed437
that, NEAT1 affects the course of PD by another438
micro RNA related mechanism. miR-221 is one of439
the most abundant miRNAs in the human CNS, and440
plays an important role in promoting neurite out-441
growth and neuronal differentiation [53]. A direct442
target of miR-221 micro RNA is PTEN (Phosphatase443
and tensin homolog), a tumor suppressor which has444
also been found to be involved in the course of vari-445
ous neurodegenerative diseases, such as Alzheimer’s446
disease (AD), amyotrophic lateral sclerosis and PD447
[54]. Several papers have reported miR-221 down-448
regulation in serum samples of PD patients and449
proposed the possibility of this RNA serving as a450
biomarker of the disease [55, 56]. In a study Geng451
et al. found that MPP+exposure of SH-SY5Y cells452
resulted in upregulation of NEAT1 and downregu-453
lation of miR-221 expression in a dose- and time454
dependent manner [57] (Fig. 3). However, NEAT1455
specific siRNA treatment increased miR-221 expres-456
sion and diminished reactive oxygen species (ROS)457
generation, which resulted in improved cell viability458
and decreased apoptosis. Overexpression of miR-221459
prior to MPP+treatment also diminished ROS pro-460
duction and was accompanied by decreased lactate461
dehydrogenase (LDH) release and downregulation of462
pro-inflammatory cytokines IL-1, IL-6 and TNF.463
Based on these observations NEAT1 was proposed to464
act as a molecular sponge for miR-221 (Fig. 1), and465
the conclusion was drawn that the beneficial effects of466
NEAT1 silencing could be related to decreased miR-467
221 sponging and a consequent higher availability of468
the micro RNA [57].469
Regulation of neuroinflammation by NEAT1 was470
proposed to occur via a further mechanism. Results of471
experiments by Xie et al. involving the MPP+treated 472
SH-SY5Y cell model of the disease show that 473
silencing of NEAT1 attenuated neuroinflammation 474
as indicated by the decreased levels of IL-1, IL- 475
6 and TNF [58] (Fig. 3). In line with findings 476
of others, NEAT1 knockdown improved cell viabil- 477
ity and decreased apoptosis rate. RNA pull down 478
and immunoprecipitation assays revealed a direct 479
interaction between NEAT1 and the micro RNA 480
miR-124. Silencing both NEAT1 and miR-124 in 481
MPP+exposed cells led to decreased cell viability 482
and an increase in the levels of pro-inflammatory 483
cytokines compared to that seen in the case on NEAT1 484
silencing only. These observations led to the conclu- 485
sion that NEAT1 regulates MPP+induced neuronal 486
injury in a miR-124-dependent manner [58] (Fig. 1). 487
According to recent findings of Liu et al., NEAT1 488
also interacts with miR-212-5p, thus modulating the 489
course of MPP+induced neurodegeneration via the 490
miR-212-5p/ RAB3IP miR-1301-3p and miR-221 491
pathway [59] (Figs. 1 and 3). Treatment of SK- 492
N-SH cells with MPP+caused the downregulation 493
of miR-212-5p and upregulation of both NEAT1 494
and RAB3IP (RAB3A-interacting protein). RAB3IP 495
is known to be involved in various cell functions 496
such as autophagy, cell growth and apoptosis [59]. 497
Similarly to the observations made in the in vitro 498
PD models mentioned previously, NEAT1 knock- 499
down in MPP+exposed cells reversed the decreased 500
superoxide dismutase and increased LDH activity 501
and diminished ROS production, thus promoting cell 502
viability and reducing the rate of apoptosis. Interest- 503
ingly, overexpression of miR-212-5p also improved 504
cell survival and alleviated MPP+linked inflam- 505
mation and cytotoxicity. Based on their findings, 506
Liu and colleagues suggested that similarly to the 507
situation discussed above in relation to miRNAs miR- 508
1301-3p and miR-221, NEAT1 acts as a molecular 509
sponge for miR-212-5p as well, leading to the down- 510
regulation of this miRNA. Dual-luciferase reporter 511
gene assays showed that miR-212-5p directly binds 512
to RAB3IP mRNA and by this negatively reg- 513
ulates the expression of RAB3IP. In their study 514
Liu and colleagues also showed that overexpres- 515
sion of RAB3IP promoted inflammatory processes 516
and apoptosis of MPP+treated SK-N-SH cells. These 517
findings led to the conclusion that a possible mech- 518
anism of the neuroprotective effect that NEAT1 519
knockdown shows against MPP+toxicity is the higher 520
level of available miR-212-5p miRNA. The dimin- 521
ishment of miR-212-5p miRNA sponging with 522
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apoptosis by indirectly causing the downregulation of524
RAB3IP.525
NEAT1 IN NEUROPROTECTIVE ROLE526
Opposite to the studies discussed above, the527
findings of Simchovitz and colleagues argue for a pro-528
tective role of NEAT1 upregulation in the course of529
PD [18]. They reported that in postmortem substantia530
nigra PD samples NEAT1 was significantly upregu-531
lated compared to healthy controls. The significant532
difference was found to be due to the upregula-533
tion of the long NEAT1 variant, as upregulation of534
NEAT1L was more prominent than the expression535
change of both isoforms together (fold change: 2.3536
and 1.7, NEAT1L and NEAT1L+S, respectively).537
In vitro experiments yielded similar results: upon538
paraquat (PQ) and tBHP (t-butyl hydroperoxide)539
induced oxidative stress significant NEAT1 upreg-540
ulation was observed in HEK-293T and SH-SY5Y541
cell lines, primarily due to the increased expression542
of the long variant (fold change: 7 and 2.5, NEAT1L543
and NEAT1L+S, respectively) (Fig. 4). In murine544
neuronal primary cultures (GSE70368), -syn over-545
expressing cells also manifested upregulated NEAT1546
expression as compared to their non-overexpressing547
counterparts.548
Investigation of PQ effect on paraspeckle forma-549
tion revealed that the mean number of paraspeckles550
in a nucleus was increased by 60% in HEK-293T551
cells following PQ exposure, while no change was552
observed either in the number of paraspeckle form-553
ing cells or in the nuclear localization of NEAT1L.554
Thus, upregulation of the lncRNA upon PQ expo-555
sure seemed to be in correlation with the elevation556
in the number of paraspeckles. In light of this,557
it was proposed that in PD substantia nigra the558
elevated NEAT1L expression could be a cellular559
response to neuronal stress in order to promote560
enhanced formation of paraspeckles [18]. Silencing561
of NEAT1 decreased both the proportion of cells562
forming paraspeckles and the number of paraspeck-563
les/nucleus. In addition, this also led to a decrease in564
the number of mitochondria, indicating that depletion565
of the lncRNA also affects mitochondrial abundance566
(Fig. 4). Treatments with NEAT1 siRNA exacer-567
bated oxidative stress provoked cell death; however,568
this could be reversed by the LRRK2 (Leucine-rich569
repeat kinase 2) inhibitor PF-06447475. This obser-570
vation gave ground to the suggestion that NEAT1571
improves cell viability by an LRRK2-dependent572
manner. The finding that LRRK2 protein interacts 573
with the paraspeckle proteins NONO and SFPQ 574
supports this assumption [18, 60]. Simchovitz and 575
colleagues proposed that NEAT1 acts as a bona fide 576
LRRK2 inhibitor via binding the LRRK2 protein in 577
paraspeckles. Mutations of the LRRK2 gene are one 578
of the most common genetic causes of both sporadic 579
and familial PD [61]. Several pathogenic LRRK2 580
mutations have been identified to cause increased 581
kinase activity, and overactivation of LRRK2 has 582
been found to cause disturbances in lysosomal home- 583
ostasis, microglial overactivation, phosphorylated tau 584
accumulation and mitochondrial function (reviewed 585
in [61, 62]). Since LRRK2 dysfunction plays crucial 586
role in PD pathology [63], restoration of the impaired 587
function of the kinase is an appealing approach for 588
the treatment of the disease. There has been inten- 589
sive research focusing on the development of kinase 590
inhibitors for PD therapy (reviewed in [64]), and 591
the finding of NEAT1 acting as a natural LRRK2 592
inhibitor could make upregulation of NEAT1 a tar- 593
get of such drug research. The promoter region of 594
NEAT1 lncRNA contains a PPAR (Peroxisome 595
proliferator-activated receptor alpha) binding site 596
thus NEAT1 expression induction could be achieved 597
by the use of PPAR activators. Indeed, treatment 598
with both PPAR agonist fenofibrate and 3-hydroxy- 599
3-methylglutaryl-coenzyme A inhibitor simvastatin 600
led to the upregulation of NEAT1 expression, leading 601
to a more prominent rise in the amount of the long 602
lncRNA variant. In vitro experiments demonstrated 603
that administration of fenofibrate and simvastatin 604
increased viability of PQ and tBHP treated cells 605
(Fig. 4). In HEK-293T cells, the beneficial effect of 606
NEAT1 upregulation on cell survival was abolished 607
after co-treatment with PQ and LRRK2 inhibitor, 608
strengthening the notion that NEAT1 exerts its neu- 609
roprotective effects via mediating LRRK2 function 610
(Fig. 1). 611
Combining the results obtained from human sam- 612
ples and in vitro models of the diseases it was 613
proposed that NEAT1 upregulation in the substantia 614
nigra reflects the accumulation of the lncRNA and 615
the enhanced formation of paraspeckles in the dying 616
neurons, and is therefore a hallmark of neurodegen- 617
eration. Simchovitz et al. proposed that the reason 618
behind the upregulation of NEAT1 in dopaminer- 619
gic neurons could be to enhance the formation of 620
nuclear paraspeckles as a mechanism of protecting 621
neurons from the damage mediated by LRRK2 [18]. 622
The fact that HOTAIR (Hox transcript antisense inter- 623
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identified as an LRRK2-dependent modifier of PD625
pathology also support this notion [65]. Opposite to626
NEAT1, however, HOTAIR was reported to enhance627
LRRK2 gene expression thus propagating the628
disease.629
DISCUSSION630
The diverse interaction of NEAT1 with a broad631
range of molecules demonstrates well the com-632
plex ways in which this lncRNA can regulate cell633
functions. Despite intensive research and a rapidly634
growing body of evidence of the involvement of635
NEAT1 in PD, it is still not elucidated whether this636
lncRNA has an ameliorating or an exacerbating effect637
on disease progression. The controversial results of638
different research groups may originate from the dif-639
ferent disease models implemented. The observation640
that the effect of NEAT1 upregulation varies depend-641
ing on the agent used for disease modeling raises the642
possibility that the contrasting results may at least643
partly reflect differences of causative or consequen-644
tial nature of PD insults. Studies with genetic models645
(either knockout or transgene) of the disease which646
are more likely to represent pathological changes that647
are causative in the development of the disorder might648
be useful to clarify questions in this respect. This calls649
attention to difficulties stemming from the complex650
patho-mechanism behind neurodegenerative disor-651
ders: even the acknowledged and well established in652
vitro and in vivo models are hardly, if at all, able to653
mimic precisely the complexity of pathological pro-654
cesses. Thus, results obtained from disease models655
should always be interpreted with great caution.656
It is worth pointing out that although in the context657
of PD NEAT1 downregulation improved cell viabil-658
ity and decreased apoptosis in MPTP/MPP+models659
of the disease, NEAT1 upregulation was found to660
have a protective effect in in vitro models induced by661
oxidative stressors such as PQ and tBPH. This implies662
that the effect of NEAT1 is likely context dependent.663
MPTP/MPP+is a mitochondrial toxin which inhibits664
complex I of the mitochondrial respiratory chain,665
resulting in the disruption of ATP synthesis and ROS666
generation. MPTP also damages dopamine storage667
of cells, a feature considered to play a key role in668
the selective loss of dopaminergic neurons (reviewed669
in [66]). PQ is a herbicid, which, by interfering670
with photosynthetic electron transport in plants, leads671
to the production of superoxide. Though PQ has672
been linked to the production of ROS and accumula-673
tion of -syn aggregates in dopaminergic neurons in674
experimental models of PD, the exact way by which 675
it damages dopaminergic cells is not fully elucidated 676
[67, 68]. Such ambiguous results regarding the role 677
of NEAT1 in different PD models could be partly due 678
to the different pathological effects the implemented 679
toxins exert. 680
The role of NEAT1 is controversial not only in PD, 681
but in cancer and other neurodegenerative diseases as 682
well, such as Huntington’s disease (HD) and AD. 683
Sunwoo et al. found NEAT1 to be upregulated 684
in brain samples of both HD patients and the R6/2 685
HD mouse model of the disease. However, var- 686
ious in vitro models, such as mutant huntingtin 687
(mHtt)-transfected neuro2A cells and mouse stri- 688
atal neuron-derived cell lines (STHdh) did not show 689
upregulation of the lncRNA. Despite the fact that 690
no change was observed in NEAT1 expression in 691
the above in vitro HD models, transfection with the 692
NEAT1 short isoform vector in the mouse neuroblas- 693
toma cell line Neuro2A improved cell viability under 694
H2O2-induced oxidative stress [69]. These ambigu- 695
ous findings were proposed to reflect the lack of in 696
vitro models’ ability to portray the complex underly- 697
ing pathophysiological mechanisms of HD [69]. This 698
again calls attention to the complexity of neurodegen- 699
erative diseases and might offer explanation for the 700
seemingly controversial results acquired from studies 701
implementing different models. 702
The finding that NEAT1 transfection improved cell 703
viability in H2O2-induced oxidative stress is in line 704
with the findings of Simchovitz et al., who also found 705
that NEAT1 upregulation increased cell viability after 706
treatment with ROS generators PQ or tBHP [18]. 707
Chanda and colleagues detected consistent and sig- 708
nificant upregulation of NEAT1 not only in animal 709
models, but also in mHtt expressing in vitro models 710
of the disease. Knockdown of NEAT1 led to a sig- 711
nificant decrease in mHtt aggregates and decreased 712
expression of TP53 (Tumor protein 53) [70]. 713
In addition to HD, NEAT1L (but not NEAT1S) 714
upregulation was reported by Chang et al. in other 715
polyglutamine (polyQ) repeat diseases, such as 716
spinocerebellar ataxia types 1, 2 and 7 [71]. Upregu- 717
lation of NEAT1 in mHtt expressing SH-SY5Y cells 718
was protective against mHtt induced toxicity, while 719
inhibition of the lncRNA decreased cell viability. 720
Interestingly, NEAT1 silencing not only increased 721
mHtt sensitivity of the cells but also augmented via- 722
bility upon treatment with the mitochondrial toxin 723
3-nitropropionic acid (3-NP) [71]. 724
Some of the observations made using AD models 725
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the beneficial role of NEAT1 silencing in MPTPT/727
MPP+PD models. In in vitro models of AD A728
(amyloid beta)-exposure enhanced NEAT1 expres-729
sion, and knockdown of the lncRNA promoted cell730
viability and diminished apoptosis [72]. NEAT1 was731
identified as a decoy for miR-107, and the lncRNA732
was proposed to aggravate A-induced cell damage733
by sponging the micro RNA [72].734
Recently Huang and colleagues proposed a fur-735
ther mechanism by which NEAT1 regulates A736
metabolism and modifies AD pathology [73]. In the737
APP/PS1 transgenic mouse model, NEAT1 overex-738
pression was found to exacerbate A production,739
whereas knockdown of the lncRNA inhibited the740
generation of amyloid deposits [73]. In the same741
animal model knockdown of the lncRNA led to an742
increase in the levels of PINK1 as well as those of743
other autophagy markers such as P62, OPTN and744
LC3. NEAT1 overexpression promoted the ubiqui-745
tination and consequent degradation of PINK1—just746
the opposite of what was seen in PD models, where747
NEAT1 was identified as a stabilizer of the pro-748
tein [45]. Based on their findings Huang et al.749
proposed that via facilitating PINK1 degradation,750
NEAT1 causes the inhibition of autophagy signal-751
ing thus impairing A clearance. This results in the752
accumulation of amyloid aggregates and propagates753
disease pathology [73].754
NEAT1 was also proposed to modulate AD755
pathology by epigenetic regulation of various genes756
due to its interaction with the PC300/CBP lysine757
acetyltransferases [74]. Knocking down the lncRNA758
affected both the acetylation and crotonylation of759
H3K27, thus impacting the transcription of several760
genes involved in endocytosis. In vitro studies involv-761
ing the human astrocytic U251 cell line showed that762
inhibition of NEAT1 impeded A uptake and degra-763
dation, suggesting a negative role of the lncRNA in764
AD pathology [74].765
Changes in NEAT1 level and the responses pre-766
sumably evoked by this have been reported to affect767
several further neurological conditions: NEAT1768
upregulation was observed in hypoxic-ischemic brain769
damage (HIBD). The change in NEAT1 expression770
was proposed to be part of a protective response771
reaction [75]. In neonatal HIBD mice, NEAT1 was772
identified to competitively bind to the micro RNA773
miR-339-5p. Sponging of miR-339-5p led to the774
upregulation of homeobox A1 (HOXA1), promoting775
of cell viability and decreased apoptosis.776
NEAT1 silencing was also reported to have a bene-777
ficial effect on age-related memory impairment [76].778
Knockdown of NEAT1 caused disruption of histone 779
3 lysine 9 demethylation (H3K9me2), a repressive 780
histone modification mark which increases with age 781
in rodent hippocampus [76]. NEAT1 overexpression 782
led to memory impairment of young mice, similar 783
to that observed in their older counterparts. NEAT1 784
knockdown, on the other hand, improved behav- 785
ior test–associated memory of mice of both age 786
groups. 787
NEAT1 depletion was reported to ameliorate mem- 788
ory impairment related to AD as well: knockdown of 789
NEAT1 led to improvement of learning and cogni- 790
tive functions of APP/PS1 transgenic mice [73]. The 791
question of whether these effects could be causally 792
linked to the changes in NEAT1 expression and 793
whether they relate to the effects observed in PD 794
models remains to be answered. 795
In addition to NEAT1 various other lncRNAs play 796
role in pathological processes of PD as it has been 797
indicated and/or proved byfindings of numerous in 798
vivo and in vitro studies (recent reviews on these: [14, 799
77, 78]). Several lncRNAs are implied to have protec- 800
tive effects against disease development (including 801
UCHL1-AS, MAPT-AS1, Mirt2), while others are 802
likely to play a detrimental role (such as HOTAIR, 803
MALAT1, lincRNA-p21, BACE1-AS, HAGLROS 804
and SNHG1) ([14, 78] and references in there). 805
The mode of action of these transcripts resemble 806
those proposed for NEAT1: among them are regu- 807
lation of SNCA expression and -syn aggregation 808
by MALAT1 (alias NEAT2) [79] and SNHG1 [80], 809
respectively, regulation of MAPT promoter activity 810
by MAPT-AS1 [81], enhancement of UCHL1 gene 811
(alias PARK5) via its anti-sense pair UCHL1-AS [82] 812
and modulation of LRRK2 mRNA stability through 813
HOTAIR [65]. Besides transcriptional and post- 814
transcriptional regulation of PARK genes, lncRNAs 815
can influence processes related to neuroinflammation 816
partly via their interaction with miRNAs (such as 817
Mirt2 lncRNA and miR-101 [83]; lincRNA-p21 and 818
miR-1277-5p [84]). Further modes of action of PD 819
related lncRNAs are autophagosomy system balance 820
maintenance, oxidative stress and dopaminergic cell 821
loss [85, 86] (reviewed in [14] and [78]). 822
CONCLUSION 823
Despite the fact that PD is one of the most com- 824
mon neurodegenerative diseases worldwide, causing 825
tremendous burden not only on the individual 826
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mechanism of the disease is still unknown. In the past828
few years lncRNAs have emerged as intriguing sub-829
jects of PD research due to the diverse functions they830
fulfill. Among lncRNAs, NEAT1 attracted particular831
interest, since its expression was found to be elevated832
both in different brain regions and also in peripheral833
blood of PD patients. Upregulation of NEAT1 has834
been detected in various in vitro and in vivo models of835
the disease however data on whether its role in disease836
progression is protective or detrimental is conflict-837
ing. Upregulated NEAT1 level was proposed to have838
a damaging effect via the interaction of the RNA with839
PINK1 protein and various micro RNAs such as miR-840
1303-3p, miR-124, miR-212-5p and miR-221 and by841
the upregulation of SNCA expression. On the other842
hand, results of Simchovitz et al. argue for the pro-843
tective role of NEAT1, based on the finding that the844
lncRNA acts as a natural LRRK2 inhibitor.845
The effects of NEAT1 on disease progression are846
contradictory in other neurodegenerative diseases847
such as HD and AD as well. The cause of this could848
be in the different models implemented by different849
research groups. Due to the complexity of these dis-850
orders, to date no in vitro or in vivo model exists851
that is capable of precisely mimicking the pathologi-852
cal mechanisms of neurodegeneration. Inconsistent853
data regarding NEAT1 effects also imply that the854
RNA acts in context dependent modes: based on the855
toxin used for modeling PD, both NEAT1 upreg-856
ulation or knockdown can prove to be protective.857
Research aiming to clarify the role and mode of858
action of this lncRNA in PD is highly warranted, since859
NEAT1 shows promise to emerge as both a promising860
biomarker and a potential therapeutic target for this861
neurodegenerative disease.862
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